Nanostream Recruits Top Talent to Support Rapid Expansion of Customer Base
News Oct 21, 2005
Nanostream has announced that Dr. Thomas J. Onofrey has joined Nanostream as director of applications development.
He brings over 10 years of experience in developing application techniques and managing research efforts in areas such as biomolecular immobilization, detection systems and assay design.
As director of applications development, Dr. Onofrey will be responsible for driving the development of analytical applications across drug discovery for Nanostream's micro parallel liquid chromatography (PLC) products.
Also, Dr. Onofrey will oversee sample projects for prospective customers and present experiment results to them.
A critical function of his role will be gathering input from customers to provide recommendations regarding enhancements and features to Nanostream products.
“Tom's deep knowledge of assay design and development will be invaluable to our customers,” said Stephen D. O'Connor, CEO of Nanostream.
“He is helping Nanostream's customers use our product to develop assays faster and to achieve higher data quality than they can get using other technologies.”
Dr. Onofrey has a track record of innovative work with liquid chromatography instrumentation for applications such as ADME assays, biomolecular immobilization and natural product synthesis.
Prior to working at Nanostream, Dr. Onofrey served as manager of R&D at Millipore, Inc., where he developed filter-based ADME assays using Millipore's membrane technology.
As a group leader of R&D for Nanogen, he developed immobilization DNA technology for Nanogen's molecular biology workstation.
He completed his post-doctoral program at the University of California at Irvine in synthetic methodology and natural product synthesis.
Dr. Onofrey received a BA in chemistry from the College of the Holy Cross in 1989 and his PhD in organic chemistry from Dartmouth College in 1996. He has authored over 25 publications and posters in addition to holding numerous patents.
“At Nanostream, we collaborate with our customers every day to develop new applications and to expand our product portfolio,” said Dr. Onofrey.
“Our innovative and multidisciplinary team is poised to achieve some incredible results. We need to grow to continue to deliver excellent service as our customer base expands, and we are looking for enthusiastic candidates who are ready for the never-ending challenges and rewards of working at Nanostream.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
World Congress on Recent Advances in Aquaculture Research & Fisheries
Jun 10 - Jun 11, 2019